169 related articles for article (PubMed ID: 19697398)
1. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.
Van Houtte M; Picchio G; Van Der Borght K; Pattery T; Lecocq P; Bacheler LT
J Med Virol; 2009 Oct; 81(10):1702-9. PubMed ID: 19697398
[TBL] [Abstract][Full Text] [Related]
2. Comparison of nine resistance interpretation systems for HIV-1 genotyping.
Stürmer M; Doerr HW; Staszewski S; Preiser W
Antivir Ther; 2003 Jun; 8(3):239-44. PubMed ID: 12924541
[TBL] [Abstract][Full Text] [Related]
3. Antivirogram or phenosense: a comparison of their reproducibility and an analysis of their correlation.
Wang K; Samudrala R; Mittler JE
Antivir Ther; 2004 Oct; 9(5):703-12. PubMed ID: 15535407
[TBL] [Abstract][Full Text] [Related]
4. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
[TBL] [Abstract][Full Text] [Related]
5. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures.
Winters B; Van Craenenbroeck E; Van der Borght K; Lecocq P; Villacian J; Bacheler L
J Virol Methods; 2009 Dec; 162(1-2):101-8. PubMed ID: 19654022
[TBL] [Abstract][Full Text] [Related]
6. Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay.
Choi JY; Kwon OK; Choi SY; Park YK; Kim SS
J Clin Virol; 2011 Jan; 50(1):19-25. PubMed ID: 20970373
[TBL] [Abstract][Full Text] [Related]
7. Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks.
Kjaer J; Høj L; Fox Z; Lundgren JD
HIV Med; 2008 Oct; 9(8):642-52. PubMed ID: 18631257
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral drug resistance testing.
Sen S; Tripathy SP; Paranjape RS
J Postgrad Med; 2006; 52(3):187-93. PubMed ID: 16855319
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype.
Zazzi M; Romano L; Venturi G; Shafer RW; Reid C; Dal Bello F; Parolin C; Palù G; Valensin PE
J Antimicrob Chemother; 2004 Feb; 53(2):356-60. PubMed ID: 14688053
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ; Chappey C; Parkin NT; Miller MD
Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
[TBL] [Abstract][Full Text] [Related]
11. [Clinical utility of drug resistance testing].
Sugiura W
Nihon Rinsho; 2002 Apr; 60(4):703-10. PubMed ID: 11968776
[TBL] [Abstract][Full Text] [Related]
12. A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms.
Ross L; Boulmé R; Fisher R; Hernandez J; Florance A; Schmit JC; Williams V
AIDS Res Hum Retroviruses; 2005 Nov; 21(11):933-9. PubMed ID: 16386109
[TBL] [Abstract][Full Text] [Related]
13. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Paredes R; Tzou PL; van Zyl G; Barrow G; Camacho R; Carmona S; Grant PM; Gupta RK; Hamers RL; Harrigan PR; Jordan MR; Kantor R; Katzenstein DA; Kuritzkes DR; Maldarelli F; Otelea D; Wallis CL; Schapiro JM; Shafer RW
PLoS One; 2017; 12(7):e0181357. PubMed ID: 28753637
[TBL] [Abstract][Full Text] [Related]
14. AIDS in the Third World: how to stop the HIV infection?
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
[TBL] [Abstract][Full Text] [Related]
15. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
[TBL] [Abstract][Full Text] [Related]
16. Interpreting resistance data for HIV-1 therapy management--know the limitations.
Van Laethem K; Vandamme AM
AIDS Rev; 2006; 8(1):37-43. PubMed ID: 16736950
[TBL] [Abstract][Full Text] [Related]
17. Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.
Hill A; Walmsley S; Clotet B; Molto J
HIV Med; 2006 Mar; 7(2):67-74. PubMed ID: 16420251
[TBL] [Abstract][Full Text] [Related]
18. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.
Torti C; Quiros-Roldan E; Keulen W; Scudeller L; Lo Caputo S; Boucher C; Castelli F; Mazzotta F; Pierotti P; Been-Tiktak AM; Buccoliero G; De Gennaro M; Carosi G; Tinelli C;
J Infect Dis; 2003 Jul; 188(2):194-201. PubMed ID: 12854073
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq E
Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
[TBL] [Abstract][Full Text] [Related]
20. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.
Vermeiren H; Van Craenenbroeck E; Alen P; Bacheler L; Picchio G; Lecocq P;
J Virol Methods; 2007 Oct; 145(1):47-55. PubMed ID: 17574687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
